The role of PET imaging in lymphoma

British Journal of Haematology

Volumn 126, Issue 6, 2004, Pages 772-784

  Burton, Catherine ^a   Ell, Peter ^b   Linch, David ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

2 fluoro 2 deoxy D glucose positron emission tomography; Hodgkin lymphoma disease; Lymphoma; Non Hodgkin's lymphoma; Positron emission tomography

Indexed keywords

FLUORINE 18; TRACER;

CANCER DIAGNOSIS; CANCER STAGING; DIAGNOSTIC IMAGING; FOLLOW UP; HISTOLOGY; HODGKIN DISEASE; HUMAN; ISOTOPE LABELING; LYMPHOMA; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TISSUE TYPES;

ADULT; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASM STAGING; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 4644222796     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.05069.x     Document Type: Review

References (82)

1. Antoch, G., Vogt, F., Freudenberg, L., Nazaradeh, F., Goehde, S., Barkhausen, J., Dahmen, G., Bockisch, A., Debatin, J. & Ruehm, S. (2003) Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. Journal of American Medical Association, 290, 3199-3206.
2. Bangerter, M., Moog, F., Buchmann, I., Kotzerke, J., Griesshammer, M, Hafner, M., Elsner, K., Frickhofen, N., Reske, S. & Bergmann, L. (1998) Whole-body 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Annals of Oncology, 9, 1117-1122.
3. Bangerter, M., Kotzerke, J., Griesshammer, Elsner, K., Reske, S. & Bergmann, L. (1999) Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncology, 38, 799-804.
4. Barthel, H., Cleij, M., Collingridge, D., Hutchinson, O., Osman, S., He, Q., Luthra, S., Brady, F., Price, P. & Aboagye, E. (2003) 3′-Deoxy-3′-[18F]Fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Research, 63, 3791-3798.
5. Becherer, A., Mitterbauer, M., Jaeger, U., Kalhs, P., Greinix, H., Karanikas, G., Potzi, C., Raderer, M., Dudczak, R. & Kletter, K. (2002) Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia, 16, 260-267.
6. Ben-Haim, S., Bar-Shalom, R., Israel, O., Haim, N., Epelbaum, R., Ben-Shachar, M., Gaitini, D., Kolodny, G. & Front, D. (1996) Utility of gallium-67 scintigraphy in low-grade non-Hodgkin's lymphoma. Journal of Clinical Oncology, 14, 1936-1942.
7. Buchmann, I., Reinhardt, M., Elsner, K., Bunjes, D., Altehoefer, C., Finke, J., Moser, E., Glatting, G., Kotzerke, J., Guhlmann, C., Schirrmeister, H. & Reske, S. (2001) 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer, 91, 889-899.
8. Canellos, G. (1988) Residual mass in lymphoma may not be residual disease. Journal of Clinical Oncology, 6, 931.
9. Carr, R., Barrington, S., Madan, B., O'Doherty, M., Saunders, C., van der Walt, J. & Timothy, A. (1998) Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood, 91, 3340-3346.
10. Charron, M., Beyer, T., Bohnen, N.N., Kinahan, P.E., Dachille, M., Jerin, J., Nutt, R., Meltzer, C.C., Villemagne, V. & Townsend, D.W. (2000) Image analysis in patients with cancer studied with a combined PET and CT scanner. Clinical Nuclear Medicine, 25, 905-910.
11. Coiffier, B., Gisselbrecht, C., Vose, J., Tilly, H., Herbrecht, R., Bosly, A. & Armitage, J. (1991) Prognostic factors in aggressive malignant lymphomas: Description and validation of prognostic index that could identify patients requiring a more intensive therapy. Journal of Clinical Oncology, 9, 211-219.
12. Cremerius, U., Fabry, U., Neuerburg, J., Zimny, M., Osieka, R. & Buell, U. (1998) Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nuclear Medicine Communications, 19, 1055-1063.
13. Cremerius, U., Fabry, U., Neuerburg, J., Zimny, M., Bares, R., Osieka, R. & Buell, U. (2001) Prognostic significance of positron emission tomography using fluorine-18-fluoro-deoxyglucose in patients treated for malignant lymphoma. Nuklearmedizin, 40, 23-30.
14. Cremerius, U., Fabry, U., Wildberger, J., Zimny, M., Reinartz, P., Nowak, B., Schaefer, W., Buell, U. & Osieka, R. (2002) Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplantation, 30, 103-111.
15. De Wit, M., Bumann, D., Beyer, W., Herbst, K., Clausen, M. & Hossfeld, D. (1997) Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Annals of Oncology, 8, 57-60.
16. De Wit, M., Bohuslavizki, K., Buchert, R., Bumann, D., Clausen, M. & Hossfeld, D. (2001) 18FDG-PET following treatment as valid predictor for disease free survival in Hodgkin's lymphoma. Annals of Oncology, 12, 29-37.
17. Elstrom, R., Guan, L., Baker, G., Nakhoda, K., Vergilio, I., Zhuang, H., Pitsilos, S., Bagg, A., Downs, L., Mehrotra, A., Kim, S., Alavi, A. & Schuster, S. (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood, 101, 3875-3876.
18. Freudenberg, L.S., Antoch, G., Schutt, P., Beyer, T., Jentzen, W., Muller, S.P., Gorges, R., Nowrousian, M.R., Bockisch, A. & Debatin, J.F. (2004) FDG-PET/CT in re-staging of patients with lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 3, 325-329.
19. Friedberg, J. & Chengazi, V. (2003) PET scans in the staging of lymphoma: current status. Oncologist, 8, 438-447.
20. Friedberg, J., Fischman, A., Neuberg, D., Kim, H., Takvorian, T., Ng, A., Mauch, P., Canellos, G. & van den Abbeele, A. (2004) FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leukaemia and Lymphoma, 45, 85-92.
21. Front, D., Bar-Shalom, R., Mor, M., Haim, N., Epelbaum, R., Frenkel, A., Gaitini, D., Kolodny, G. & Israel, O. (1999) Hodgkin disease: prediction of outcome with 67-Ga scintigraphy after one cycle of chemotherapy. Radiology, 210, 487-491.
22. Front, D., Bar-Shalom, R., Mor, M., Haim, N., Epelbaum, R., Frenkel, A., Gaitini, D., Kolodny, G. & Israel, O. (2000) Aggressive non-Hodgkin lymphoma: early prediction of outcome with 67-Ga scintigraphy. Radiology, 214, 253-257.
23. Glenn, L. & Kumar, P. (1991) The residual mediastinal mass following radiation therapy for Hodgkin's disease. American Journal of Clinical Oncology, 14, 16-24.
24. Guay, C., Lepine, M., Verreault, J. & Benard, F. (2003) Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. Journal of Nuclear Medicine, 44, 1225-1231.
25. Hoffman, M., Kletter, K., Diemling, M., Becherer, A., Pfellel, F. & Petkov, V. (1999) Positron emission tomography with fluorine-18-2-fluoro-2- deoxy-D-glucose (F18-FDG) does not visualise extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Annals of Oncology, 10, 1185-1189.
26. Hoffman, M., Kletter, K., Becherer, A., Jager, U., Chott, A. & Raderer, M. (2003) 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology, 64, 336-340.
27. Hong, S., Hahn, J., Lee, J., Bae, S. & Youn, M. (2003) 18F-fluorodeoxyglucose positron emission tomography in the staging of malignant lymphoma compared with CT and 67-Ga scan. Yonsei Medical Journal, 44, 779-786.
28. Hoskin, P. (2002) FDG PET in the management of lymphoma: a clinical perspective. European Journal of Nuclear Medicine, 29, 449-451.
29. Hueltenschmidt, B., Sautter-Bihl, M., Lang, O., Maul, F., Fischer, J., Mergenthaler, H. & Bihl, H. (2001) Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer, 91, 302-310.
30. Hustinx, R., Lemaire, C., Jerusalem, G., Moreau, P., Cataldo, D., Duysinx, B., Aerts, J., Fassotte, M.-F., Foidart, J. & Luxen, A. (2003) Whole-body tumor imaging using PET and 2-18F- fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG. Journal of Nuclear Medicine, 44, 533-539.
31. Israel, O., Front, D., Lam, M., Ben-Haim, S., Kleinhaus, U., Ben-Shachar, M., Robinson, E. & Kolodny, G. (1988) Gallium 67 imaging in monitoring lymphoma response to treatment. Cancer, 61, 2439-2443.
32. Jaffe, E., Harris, N., Stein, H. & Vardiman, J. (2001) Pathology and Genetics. Tumours of Haemopoietic and Lymphoid Tissues. World Health Organisation Classification of Tumours. Oxford University Press.
33. 123 I] iodo-alpha-methyl-tyrosine in GLC4 tumor cells: comparison with L-1-[11C]-tyrosine. European Journal of Nuclear Medicine, 26, 972.
34. Jager, P., Vaalburg, W., Pruim, J., de Vries, E., Langen, K.-J. & Piers, D. (2001) Radiolabeled amino acids: Basic aspects and clinical applications in oncology. Journal of Nuclear Medicine, 42, 432-442.
35. Jerusalem, G., Beguin, Y., Fassotte, M., Najjar, F., Paulus, P., Rigo, P. & Fillet, G. (1999) Whole body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's Disease and Non-Hodgkin's Lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood, 94, 429-433.
36. Jerusalem, G., Beguin, Y., Fassotte, M., Najjar, F., Paulus, P., Rigo, P. & Fillet, G. (2000) Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica, 85, 613-618.
37. Jerusalem, G., Beguin, Y., Fassotte, M., Najjar, F., Paulus, P., Rigo, P. & Fillet, G. (2001a) Whole body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica, 86, 266-273.
38. Jerusalem, G., Beguin, Y., Najjar, F., Hustinx, R., Fassotte, M., Rigo, P. & Fillet, G. (2001b) Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Annals of Oncology, 12, 825-830.
39. Jerusalem, G., Beguin, Y., Fassotte, M., Belhocine, T., Hustinx, R., Rigo, P. & Fillet, G. (2003) Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Annals of Oncology, 14, 123-130.
40. Jochelson, M., Mauch, P., Balikian, J., Rosenthal, D. & Canellos, G. (1985) The significance of the residual mediastinal mass in treated Hodgkin's disease. Journal of Clinical Oncology, 3, 637-640.
41. Kole, A., Plaat, B., Hoekstra, H., Vaalburg, W. & Molenaar, W. (1999) FDG and L-[1-11C]-tyrosine imaging of soft-tissue tumors before and after therapy. Journal of Nuclear Medicine, 40, 381-386.
42. Kostakoglu, L. & Goldsmith, S. (2000) Positron emission tomography in lymphoma: comparison with computed tomography and gallium-67 single photon emission computed tomography. Clinical Lymphoma, 1, 67-74.
43. Kostakoglu, L. & Goldsmith, S. (2003) 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung and colorectal carcinoma. Journal of Nuclear Medicine, 44, 224-239.
44. Kostakoglu, L., Leonard, J.P., Kuji, I., Coleman, M., Vallabhajosula, S. & Goldsmith, S. (2002a) Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer, 94, 879-888.
45. Kostakoglu, L., Coleman, M., Leonard, J., Kuji, I., Zoe, H. & Goldsmith, S. (2002b) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. Journal of Nuclear Medicine, 43, 1018-1027.
46. Kubota, R., Yamada, S., Kubota, K., Ishiwata, K., Tamahashi, N. & Ido, T. (1992) Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. Journal of Nuclear Medicine, 33, 1972-1980.
47. Kubota, R., Kubota, K., Yamada, S., Tada, M., Takahashi, T., Iwata, R. & Tamahashi, N. (1995) Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. Journal of Nuclear Medicine, 36, 484-492.
48. Leibenhaut, M., Hoppe, R., Efron, B., Halpern, J., Nelsen, T. & Rosenberg, S. (1989) Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease. Journal of Clinical Oncology, 7, 81-91.
49. Leskinen-Kallio, S., Ruotsalainen, U., Nagren, K., Teras, M. & Joensuu, H. (2003) Uptake of 18F-Fluoro-Tyrosine: preliminary evaluation and comparison with 18F-FDG, Journal of Nuclear Medicine, 44, 533-539.
50. Lowe, V. & Wiseman, G. (2002) Assessment of lymphoma treatment using 18F-FDG PET. Journal of Nuclear Medicine, 43, 1028-1030.
51. Maisey, N., Hill, M., Webb, A., Cunningham, D., Flux, G., Padhani, A., Ott, R., Norman, A. & Bishop, L. (2000) Are 18-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? European Journal of Cancer, 36, 200-206.
52. Mauch, P., Larson, D., Osteen, R., Silver, B., Yeap, B., Canellos, G., Weinstein, H., Rosenthal, D., Pinkus, G. & Jochelson, M. (1990) Prognostic factors for positive surgical staging in patients with Hodgkin's disease. Journal of Clinical Oncology, 8, 257-265.
53. Mikhaeel, N., Timothy, A., O'Doherty, M., Hain, S. & Maisey, M. (2000) 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT. Leukaemia and Lymphoma, 39, 543-553.
54. Moog, F., Bangerter, M., Diederichs, C., Guhlmann, A., Kotzerke, J., Merkle, E., Kolokythas, O., Herrmann, F. and Reske, S. (1997) Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology, 203, 795-800.
55. Najjar, F., Hustinx, R., Jerusalem, G., Fillet, G. & Rigo, P. (2001) Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL). Cancer Biotherapeutics Radiopharmaceuticals, 16, 297-304.
56. Naumann, R., Beuthien-Baumann, B., Reiss, A., Schulze, J., Hanel, A., Bredow, J., Kuhnel, G., Kropp, J., Hanel, M., Laniado, M., Kotzerke, J. & Ehninger, G. (2004) Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. British Journal of Cancer, 90, 620-625.
57. Ng, A., Weeks, J., Mauch, P. & Kuntz, K. (1999) Laparotomy versus no laparotomy in the management of early-stage, favorable-prognosis Hodgkin's disease: a decision analysis. Journal of Clinical Oncology, 17, 241-252.
58. Nuutinen, J., Leskinen, S., Lindholm, P., Soderstrom, K., Nagren, K., Huhtala, S. & Minn, H. (1998) Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas. European Journal of Nuclear Medicine, 25, 729-735.
59. O'Doherty, M., Macdonald, E., Barrington, S., Mikhaeel, N. & Schey, S. (2002) Positron emission tomography in the management of lymphomas. Clinical Oncology, 14, 415-426.
60. Partridge, S., Timothy, A., O'Doherty, M., Hain, S., Rankin, S. & Mikhaeel, N. (2000) 2-Fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Annals of Oncology, 11, 1273-1279.
61. Paul, R. (1987) Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for the detection of lymphoma. Journal of Nuclear Medicine, 28, 288-292.
62. Radford, J., Cowan, R., Flanagan, M., Dunn, G., Crowther, D., Johnson, R. & Eddleston, B. (1988) The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. Journal of Clinical Oncology, 6, 940-946.
63. Radford, J., Eardley, A., Woodman, C. & Crowther, D. (1997) Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. British Medical Journal, 314, 343-346.
64. Rodriguez, M., Rehn, S., Ahstrom, H., Sundstrom, C. & Glimelius, B. (1995) Predicting malignacy grade with PET in non-Hodgkin's lymphoma. Journal of Nuclear Medicine, 36, 1790-1796.
65. Romer, W., Hanauske, A., Ziegler, S., Thodtmann, R., Weber, W., Fuchs, C., Enne, W., Herz, M., Nerl, C., Garbrecht, M. & Schwaiger, M. (1998) Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood, 91, 4464-4471.
66. Segall, G. (2001) FDG PET imaging in patients with lymphoma: a clinical perspective. Journal of Nuclear Medicine, 42, 609-610.
67. Shen, Y., Kao, A. & Yen, R. (2002) Comparison of 18F-fluoro-2- deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Oncology Reports, 9, 321-325.
68. Shields, A., Grierson, J., Dohmen, B., Machulla, H., Stayanoff, J., Lawhorn-Crews, J., Obradovich, J., Muzik, O. & Mangner, T. (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nature Medicine, 4, 1334-1336.
69. Spaepen, K., Stroobants, S., Dupont, P., Thomas, J., Vandenberghe, P., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L. & Verhoef, G. (2001a) Can positron emission tomography with 18F-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? British Journal of Haematology, 115, 272-278.
70. Spaepen, K., Stroobants, S., Dupont, P., Van Steenweghen, S., Thomas, J., Vandenberghe, P., Vanuytsel, L., Bormans, G., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L. & Verhoef, G. (2001b) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in Non-Hodgkin's Lymphoma: Is [18F] FDG-PET a valid alternative to conventional diagnostic methods? Journal of Clinical Oncology, 19, 414-419.
71. Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J., De Groot, T., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L. & Verhoef, G. (2002) Early restaging positron emission tomography with 18F- fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's Lymphoma. Annals of Oncology, 13, 1356-1363.
72. Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Maertens, J., Bormans, G., Thomas, J., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L. & Verhoef, G. (2003) Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood, 102, 53-59.
73. Surbone, A., Longo, D., De Vita, V., Ihde, D., Duffey, P., Jaffe, E., Solomon, D., Hubbard, S. & Young, R. (1988) Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. Journal of Clinical Oncology, 6, 1832-1837.
74. Sutinen, E., Jyrkkio, S., Varpula, M., Lindholm, P., Gronroos, T., Lehikoinen, P., Teras, M. & Minn, H. (2000) Nodal staging of lymphoma with whole-body PET: Comparison of HC-methionine and FDG. Journal of Nuclear Medicine, 41, 1980-1988.
75. Torrey, M., Poen, J. & Hoppe, R. (1997) Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies. Journal of Clinical Oncology, 15, 1123-1130.
76. Wagner, M., Seitz, U., Buck, A., Neumaier, B., Schultheiss, S., Bangerter, M., Bommer, M., Leithauser, F., Wawra, E., Munzert, G. & Reske, S. (2003) 3′-[18F]fluoro-3′-deoxythymidine. ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in amurine B-Cell lymphoma model and in the human disease, Cancer Research, 63, 2681-2687.
77. Weeks, J., Yeap, B., Canellos, G. & Shipp, M. (1991) Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. Journal of Clinical Oncology, 9, 1196-1203.
78. Weihrauch, M., Re, D., Scheidhauer, K., Ansen, S., Dietlein, M., Bischoff, S., Bohlen, H., Wolf, J., Schicha, H., Diehl, V. & Tesch, H. (2001) Thoracic positron emission tomography using18F- fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood, 98, 2930-2934
79. Weihrauch, M., Re, D., Bischoff, S., Dietlein, M., Scheidhauer, K., Krug, F., Ansen, S., Franklin, J., Bohlen, H., Wolf, J., Schicha, H., Diehl, V. & Tesch, H. (2002) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Annals of Hematology, 81, 20-25.
80. Weihrauch, M., Dietlein, M., Schicha, H., Diehl, V. & Tesch, H. (2003) Prognostic significance of 18F- fluorodeoxyglucose positron emission tomography in lymphoma. Leukaemia and Lymphoma, 44, 15-22.
81. Wirth, A., Seymour, J., Hicks, R., Ware, R., Fisher, R., Prince, M., MacManus, M., Ryan, G., Januszewicz, H. & Wolf, M. (2002) Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. American Journal of Medicine, 112, 262-268.
82. Zinzani, P., Magagnoli, M., Chierichetti, F., Zompatori, M., Garraffa, G., Bendandi, M., Gherlinzoni, F., Cellini, C., Stefoni, V., Ferlin, G. & Tura, S. (1999) The role of positron emission tomography (PET) in the management of lymphoma patients. Annals of Oncology, 10, 1181-1184.